Area of research
Cancer Research · Reproductive Medicine
Research interest
Research interests include Ovarian cancer diagnosis and treatment, Breast Cancer Treatment Studies, Estrogen and related hormone effects, and Endometrial and Cervical Cancer Treatments.
Efficacy of Hand Cooling and Compression in Preventing Taxane-Induced Neuropathy
Therapy of early breast cancer: current status and perspectives
COGNITION-GUIDE – Genomics-Guided Targeted Post-Neoadjuvant Therapy in Patients with Early Breast Cancer: Study Design of a Multicenter, Open-Label, Umbrella Phase II Study
Delivering precision oncology in metastatic breast cancer: Clinical impact of comprehensive genomic profiling—The <scp>CATCH</scp> experience
Beyond <i>BRCA</i> deficiency: Clinical and molecular predictors of survival in patients with <i>BRCA</i> -deficient tubo-ovarian high-grade serous carcinoma
CDK4/6 Inhibition – Therapy Sequences and the Quest to Find the Best Biomarkers – an Overview of Current Programs
Reimbursement in the Context of Precision Oncology Approaches in Metastatic Breast Cancer: Challenges and Experiences
Current Treatment Practices and Prognostic Factors in Early-Stage Ovarian Cancer—An Analysis of the NOGGO/JAGO
CCNE1 and survival of patients with tubo‐ovarian high‐grade serous carcinoma: An Ovarian Tumor Tissue Analysis consortium study
COGNITION: a prospective precision oncology trial for patients with early breast cancer at high risk following neoadjuvant chemotherapy
Risk for Pelvic Metastasis and Role of Pelvic Lymphadenectomy in Node-Positive Vulvar Cancer-Results from the AGO-VOP.2 QS Vulva Study
Validated biomarker assays confirm that <scp>ARID1A</scp> loss is confounded with <scp>MMR</scp> deficiency, <scp> CD8 <sup>+</sup> TIL </scp> infiltration, and provides no independent prognostic value in endometriosis‐associated ovarian carcinomas
MCM3 is a novel proliferation marker associated with longer survival for patients with tubo-ovarian high-grade serous carcinoma
Prognostic and Immunological Significance of ARID1A Status in Endometriosis-Associated Ovarian Carcinoma
Wie hat sich die Anwendung von adjuvanter zu neoadjuvanter Chemotherapie beim frühen Mammakarzinom verändert? – Daten von 104 deutschen Brustzentren 2008-2017
Extracapsular Lymph Node Involvement in Ovarian Carcinoma
Association of differential miRNA expression with hepatic vs. peritoneal metastatic spread in colorectal cancer